Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
NCT06881251 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dupilumab
- DRUG JNJ-95475939
Study Locations (20)
Other
- CIPREC — Buenos Aires
- INAER - Investigación en Alergias y Enfermedades Respiratorias — Buenos Aires
- Instituto de Neumonologia y Dermatologia — Buenos Aires
- Derma Internacional S A — Buenos Aires
- Ceti - Centro de Estudos Em Terapias Inovadoras — Curitiba
- Hospital De Clinicas De Porto Alegre — Porto Alegre
- Hospital Das Clinicas Da Faculdade De Medicina De RPUSP HCRP — Ribeirão Preto
Texas
- Arlington Center for Dermatology — Arlington
- Center for Clinical Studies — Houston
- Progressive Clinical Research — San Antonio
California
- First OC Dermatology — Fountain Valley
- University of California Los Angeles - Division of Dermatology — Los Angeles
Indiana
- Dawes Fretzin Clinical Research Group LLC — Indianapolis
- Indiana Clinical Trial Center — Plainfield
Georgia
- Hamilton Research LLC — Alpharetta
Illinois
- DeNova Research — Chicago
North Dakota
- Red River Research Partners LLC — Fargo
Ohio
- Optima Research — Boardman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2025-02-26 |
| Est. Completion | 2026-03-26 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06881251
The ClinicalTrials.gov registry entry for NCT06881251 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 442 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Dermatitis, Atopic appearing as the primary indexed condition, and to 3 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06881251 reports 20 study locations spanning 10 distinct geographic areas — top geographies include Other, Texas, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06881251 about?
NCT06881251 is a clinical study titled "A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)". The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.
What is the current status of trial NCT06881251?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 256 participants. The study started on 2025-02-26. Estimated completion is 2026-03-26.
What conditions does trial NCT06881251 study?
This clinical trial studies the following conditions: Dermatitis, Atopic. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06881251?
The interventions under investigation include: Placebo (DRUG), Dupilumab (DRUG), JNJ-95475939 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06881251?
This trial is sponsored by Janssen Research & Development, which has 442 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06881251 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, Indiana, North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.